Fig. 8: Profiling of B55α and GWL RNA expression levels in TCGA cancer-derived biopsies.

a, b RNA expression levels of B55α (a) and GWL (b) in 33 distinct cancer groups. Red and blue points represent expression levels derived from independent matching normal (N) and Tumour (T) tissue samples. White dots represent median values. The number of analysed biopsies is shown in (d). Statistical significance was determined using an unpaired two-tailed Wilcoxon test. Determined p-values were adjusted for multiple testing using the Benjamini-Hochberg procedure. Indicated significance is colour-coded to reflect the positive (red) and negative (blue) differences between T and N samples. nd – not determined, ns – not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ***** p < 0.00001. FPKM – fragments per kilobase of transcript per million mapped reads. c Scatter plot displaying differences in median B55α and GWL RNA expression levels (a, b) between tumour and matching normal tissues (T-N). d Ranked predictions of C-604 sensitivity (*ED₅₀) based on B55α and GWL RNA expression levels (a, b) in analysed biopsies. *ED₅₀ values were calculated using the indicated formula. 5% of biopsies predicted to be most sensitive to C-604 treatment (the lowest *ED₅₀) are indicated. e Scatterplot representation of predicted *ED₅₀ values. 5% of the samples with the lowest *ED₅₀ are indicated. f Proportions biopsies with the lowest predicted *ED₅₀ values (5%) in distinct groups of tumours and matching normal tissues. Total cases per group are indicated. ACC adrenocortical carcinoma, BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL cholangiocarcinoma, COAD colon adenocarcinoma, DLBC lymphoid neoplasm diffuse Large B-cell lymphoma, ESCA oesophageal carcinoma, GBM glioblastoma multiforme, HNSC head and neck squamous cell carcinoma, KICH kidney chromophobe, KIRC kidney renal clear cell carcinoma, KIRP kidney renal papillary cell carcinoma, LAML acute myeloid leukaemia, LGG brain lower grade glioma, LIHC liver hepatocellular carcinoma, LUAD Lung adenocarcinoma, LUSC Lung squamous cell carcinoma, MESO mesothelioma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PCPG pheochromocytoma and paraganglioma, PRAD prostate adenocarcinoma, READ rectum adenocarcinoma, SARC sarcoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumours, THCA thyroid carcinoma, THYM thymoma, UCEC uterine corpus endometrial carcinoma, UCS uterine carcinosarcoma, UVM uveal melanoma.